Revive Therapeutics Ltd (RVVTF)

[ragstorum]

Absolutely, Longhorn. Good chance that Bucillamine and Molnupiravir are on that shortlist, with my bet on buc hitting the finish line first.

Despite the hype machine that Merck is trying to build around mol right now, their Phase3 may run into snags.

(repost)
https://www.clinicaltrialsarena.com/comment/ridgeback-mercks-molnupiravir-for-covid-19-has-moa-administration-advantages-but-phase-iia-faces-execution-obstacles-may-have-value-gaps/